Template:Guidelines/NSCLC stage 3
Jump to navigation
Jump to search
NCCN Guidelines Non-Small-Cell Lung Cancer (4.2025, adapted)[1]
- Durvalumab is recommended as a consolidation immunotherapy option (regardless of PDL1 status) for patients with unresectable stage 3 NSCLC and without disease progression after treatment with definitive concurrent platinum-based chemoradiation (Category 1)